Engineering soluble T-cell receptors for therapy

FEBS J. 2021 Nov;288(21):6159-6173. doi: 10.1111/febs.15780. Epub 2021 Mar 10.

Abstract

Immunotherapy approaches that target peptide-human leukocyte antigen (pHLA) complexes are becoming highly attractive because of their potential to access virtually all foreign and cellular proteins. For this reason, there has been considerable interest in the development of the natural ligand for pHLA, the T-cell receptor (TCR), as a soluble drug to target disease-associated pHLA presented at the cell surface. However, native TCR stability is suboptimal for soluble drug development, and natural TCRs generally have weak affinities for pHLAs, limiting their potential to reach efficacious receptor occupancy levels as soluble drugs. To overcome these limitations and make full use of the TCR as a soluble drug platform, several protein engineering solutions have been applied to TCRs to enhance both their stability and affinity, with a focus on retaining target specificity and selectivity. Here, we review these advances and look to the future for the next generation of soluble TCR-based therapies that can target monomorphic HLA-like proteins presenting both peptide and nonpeptide antigens.

Keywords: T-cell receptor; affinity-enhanced; bispecific T-cell engagers; cancer immunotherapy; peptide-human leukocyte antigen.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / metabolism
  • Humans
  • Protein Binding
  • Protein Engineering / methods
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / metabolism*

Substances

  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell